Sangamo Therapeutics Inc - Asset Resilience Ratio
Sangamo Therapeutics Inc (SGMO) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2024)
This chart shows how Sangamo Therapeutics Inc's Asset Resilience Ratio has changed over time. Check Sangamo Therapeutics Inc (SGMO) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Sangamo Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Sangamo Therapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Sangamo Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Sangamo Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Sangamo Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for Sangamo Therapeutics Inc (1999–2024)
The table below shows the annual Asset Resilience Ratio data for Sangamo Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $101.64 Million | -- |
| 2023-12-31 | 21.65% | $35.80 Million | $165.32 Million | -9.85pp |
| 2022-12-31 | 31.50% | $177.19 Million | $562.51 Million | +4.12pp |
| 2021-12-31 | 27.38% | $197.68 Million | $721.92 Million | -26.97pp |
| 2020-12-31 | 54.35% | $510.09 Million | $938.55 Million | +10.11pp |
| 2019-12-31 | 44.24% | $282.05 Million | $637.52 Million | +0.25pp |
| 2018-12-31 | 43.99% | $259.71 Million | $590.39 Million | -23.49pp |
| 2017-12-31 | 67.48% | $193.48 Million | $286.74 Million | -8.83pp |
| 2016-12-31 | 76.30% | $120.47 Million | $157.89 Million | +12.08pp |
| 2015-12-31 | 64.22% | $139.52 Million | $217.24 Million | -6.88pp |
| 2014-12-31 | 71.10% | $172.93 Million | $243.21 Million | +12.44pp |
| 2013-12-31 | 58.67% | $82.63 Million | $140.84 Million | +7.94pp |
| 2012-12-31 | 50.73% | $41.87 Million | $82.53 Million | -26.41pp |
| 2011-12-31 | 77.13% | $67.37 Million | $87.34 Million | -1.44pp |
| 2010-12-31 | 78.57% | $49.50 Million | $63.00 Million | +5.63pp |
| 2009-12-31 | 72.94% | $63.78 Million | $87.44 Million | +6.00pp |
| 2008-12-31 | 66.94% | $45.42 Million | $67.85 Million | -15.07pp |
| 2007-12-31 | 82.02% | $68.81 Million | $83.90 Million | +8.12pp |
| 2006-12-31 | 73.89% | $41.22 Million | $55.78 Million | +15.81pp |
| 2005-12-31 | 58.08% | $28.45 Million | $48.98 Million | -12.86pp |
| 2004-12-31 | 70.94% | $24.63 Million | $34.73 Million | -2.71pp |
| 2003-12-31 | 73.65% | $34.05 Million | $46.23 Million | +12.29pp |
| 2002-12-31 | 61.37% | $34.50 Million | $56.23 Million | -2.09pp |
| 2001-12-31 | 63.46% | $53.95 Million | $85.02 Million | -13.96pp |
| 2000-12-31 | 77.42% | $53.36 Million | $68.92 Million | -1.93pp |
| 1999-12-31 | 79.35% | $7.30 Million | $9.20 Million | -- |
About Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a ch… Read more